Special Announcement - Now Enrolling for FDA Approved Stem Cell Study
Dr. Mitchell Sheinkop has completed training and is credentialed for the first of its kind FDA approved stem cell clinical trial for knee arthritis. Our clinic is now enrolling patients in this trial. Contact us at 312-475-1893 for details. Click here to learn more.

Meet Dr. Sheinkop, Chicago & Mt Prospect, IL, The First And Only Orthopedic Surgeon That Has Transitioned To Cellular Orthopedic Treatment

chicago des plaines il orthopedic surgeon and cellular orthopedic treatment specialistDr. Sheinkop is a Board-Certified Orthopedic Surgeon in Chicago, IL and Mt Prospect, IL. He is also a former director of the joint replacement program and Professor Emeritus at Rush University Medical Center.

Dr. Sheinkop is a leading authority on the treatment of patients with complex hip and knee disorders. In addition, he is well known for his pioneering use of computer-assisted navigation, minimally-invasive technologies and hip resurfacing techniques. Dr. Sheinkop is a graduate of the Chicago Medical School and did fellowships in pediatric orthopedics and hand surgery. He has done extensive research in the fields of uni-compartmental, minimally invasive solutions, hip resurfacing systems, and navigated arthroplasty.

Dr. Sheinkop’s list of clinical research endeavors

  1. Stem Cell Counts and the Outcome of Bone Marrow Concentrate intra-articular and intra-osseous (subchondroplasty) interventions at the knee for grades 2 and 3 OA.
    (supported in part by Celling). Ongoing
  2. Outcomes of Bone Marrow Concentrate (stem cell, platelet and growth factor) Intervention at the Knee for Grades 2 and 3 OA in 50 patients at 2 to 4 years.
    (supported in part by Regenexx)
  3. Outcomes of Intra-articular Bone Marrow Concentrate versus those of combined Intraarticular and Intraosseous interventions for grades 2 and 3 OA at the knee at one year.
    (self-funded). Ongoing
  4. How does the PRP and Mononucleated cell count affect the outcome of a BMC intervention for grades 2 and 3 Knee OA?
    (a joint project with Greyledge) Ongoing
  5. Safety and Efficacy of Percutaneous Injection of Micro-Fractured Adipose Tissue for grade 4 Osteoarthritic Knees, minimum follow-up of 18 months in 30 patients
    (supported in part by Lipogems)
  6. A Lyophilized Amniotic Fluid Clinical Trial for Grades 2 and 3 Knee OA
    (supported by MiMedx) Ongoing
  7. An Amniotic Fluid Cryopreserved Clinical Trial for Grades 2 and 3 Knee OA in 30 patients.
    (supported by MiMedx)
  8. An Amniotic Fluid Cryopreserved Clinical Trial for Grades 2 and 3 Knee OA in 45 patients.
    (sponsored by Liventa)

Dr. Sheinkop’s Feature On CBS



Pin It on Pinterest

Share This